Grufity logoGrufity logo

Bio Rad Laboratories Inc Stock Research

BIO

488.28USD+10.28(+2.15%)Delayed

Market Summary

USD488.28+10.28
Delayed
2.15%

BIO Alerts

BIO Stock Price

BIO RSI Chart

BIO Valuation

Market Cap

14.5B

Price/Earnings (Trailing)

-4

Price/Sales (Trailing)

5.18

EV/EBITDA

-3.27

Price/Free Cashflow

177.78

BIO Price/Sales (Trailing)

BIO Profitability

EBT Margin

-167.87%

Return on Equity

-37.73%

Return on Assets

-26.87%

Free Cashflow Yield

0.56%

BIO Fundamentals

BIO Revenue

Revenue (TTM)

2.8B

Revenue Y/Y

-0.34%

Revenue Q/Q

7.27%

BIO Earnings

Earnings (TTM)

-3.6B

Earnings Y/Y

152.65%

Earnings Q/Q

608.42%

Price Action

52 Week Range

344.63607.54
(Low)(High)

Last 7 days

-0.6%

Last 30 days

1.3%

Last 90 days

13.7%

Trailing 12 Months

-12.9%

BIO Financial Health

Current Ratio

5.55

Debt/Equity

0.12

Debt/Cashflow

0.16

BIO Investor Care

Buy Backs (1Y)

0.27%

Diluted EPS (TTM)

-121.25

Peers (Alternatives to Bio Rad Laboratories)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.4B
6.8B
-13.31% 3.22%
32.19
5.89
8.37% 3.64%
35.5B
4.6B
5.65% -27.02%
-8.07
7.75
1.28% -677.95%
32.5B
3.9B
-7.42% 9.05%
37.3
8.3
5.43% 13.46%
18.2B
3.0B
-10.97% -4.88%
25.66
6.11
6.68% 2.15%
15.9B
3.3B
-11.65% -27.44%
27.98
4.81
-34.64% -39.65%
MID-CAP
SMALL-CAP
2.0B
128.3M
-11.70% -1.09%
-6.37
15.61
-1.69% -73.40%
1.2B
185.3M
-5.41% -23.53%
-6
6.49
20.06% 3.42%
450.3M
105.5M
-12.44% -50.56%
-4.66
4.27
-4.55% -67.63%
405.5M
127.3M
-23.43% -69.17%
-2.54
3.19
-12.28% -38.43%
341.8M
27.8M
-23.57% -31.43%
-2.58
12.29
54.62% -83.06%
271.1M
138.6M
-29.13% -76.08%
-8.07
1.96
32.30% -57.86%
135.5M
65.0M
-20.46% -63.49%
-1.2
2.08
-23.92% -73.73%
117.4M
113.3M
-15.92% -55.18%
-12.34
1.04
-4.68% -3204.17%
54.2M
54.1M
-0.24% -45.98%
502.17
1
21.80% -72.38%

Financials for Bio Rad Laboratories

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-0.1%2,802,300,0002,804,800,0002,871,000,0002,895,800,0002,922,500,000
Gross Profit-0.2%1,567,300,0001,570,100,0001,634,000,0001,640,100,0001,638,000,000
  S&GA Expenses-1.3%827,825,000839,043,000844,146,000848,841,000877,100,000
  R&D Expenses-0.6%256,889,000258,342,000252,874,000249,231,000260,600,000
EBITDA40.2%-4,666,186,000-7,803,373,000-2,594,173,000-224,902,0005,439,651,000
EBITDA Margin40.1%-1.67-2.78-0.081.86-
Earnings Before Taxes39.9%-4,704,300,000-7,830,168,000-2,598,800,000-219,100,0005,449,100,000
EBT Margin39.9%-1.68-2.79-0.081.86-
Interest Expenses42.2%38,114,00026,795,00015,558,0005,201,0001,551,000
Net Income39.8%-3,627,500,000-6,027,400,000-1,935,000,000-93,100,0004,254,200,000
Net Income Margin39.8%-1.29-2.15-0.031.45-
Free Cahsflow-46.1%81,665,000151,523,000363,791,000459,081,000535,718,000
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets12.0%13,50212,05812,68214,37417,799
  Current Assets0.6%3,1583,1403,2503,3031,990
    Cash Equivalents-16.2%434518597802471
  Inventory4.9%719686657605572
  Net PPE-2.5%499512---
  Goodwill1.7%407400347346347
Liabilities7.8%3,8863,6053,7604,1914,114
  Current Liabilities-0.3%569571614648681
  Long Term Debt11291.6%1,19811.00---
    LT Debt, Non Current0.0%1,1971,1971,19711.00-
Shareholder's Equity13.7%9,6158,4548,92310,18313,685
  Retained Earnings9.4%9,8989,0479,21010,13813,525
  Additional Paid-In Capital3.9%447431472459442
Accumulated Depreciation0.8%1,0091,002---
Shares Outstanding-0.2%30.0030.0030.00--
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-29.3%194275498602670
Cashflow From Investing29.2%-1,207-1,705-1,702-1,661-797
Cashflow From Financing-8.6%9741,0651,0581,182-55.43
  Buy Backs72.5%2161251250.0050.00

Risks for BIO

What is the probability of a big loss on BIO?

58.5%


Probability that Bio Rad Laboratories stock will be more than 20% underwater in next one year

34.6%


Probability that Bio Rad Laboratories stock will be more than 30% underwater in next one year.

15.4%


Probability that Bio Rad Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BIO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bio Rad Laboratories was unfortunately bought at previous high price.

Drawdowns

Returns for BIO

Cumulative Returns on BIO

14.5%


10-Year Cumulative Returns

20.0%


7-Year Cumulative Returns

12.7%


5-Year Cumulative Returns

11.2%


3-Year Cumulative Returns

What are the long-term rolling returns for BIO?

FIve years rolling returns for Bio Rad Laboratories.

Annualized Returns

Which funds bought or sold BIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
MATHER GROUP, LLC.
new
-
217,393
217,393
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
35.51
1,202,530
4,484,530
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-8.34
-23,000
276,000
-%
2023-02-28
Voya Investment Management LLC
reduced
-2.73
-64,841
3,225,160
-%
2023-02-24
SRS Capital Advisors, Inc.
new
-
2,943
2,943
-%
2023-02-24
National Pension Service
unchanged
-
4,944
923,817
-%
2023-02-24
NATIXIS
reduced
-29.68
-172,612
418,388
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
102,000
12,874,000
0.14%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
added
39.32
19,116
68,116
-%
2023-02-21
MACQUARIE GROUP LTD
unchanged
-
6,943
946,943
-%

1–10 of 45

Latest Funds Activity

Are funds buying BIO calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BIO
No. of Funds

Bio Rad Laboratories News

Digital Journal

Microfluidic Cell Chips Market Research (2023 – 2030) Highlighting ....

Digital Journal,
2 days ago

Schedule 13G FIlings of Bio Rad Laboratories

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.66%
2,391,436
SC 13G/A
Feb 01, 2023
blackrock inc.
6.4%
1,582,313
SC 13G/A
Apr 11, 2022
schwartz alice n
89.7%
4,555,452
SC 13D/A
Feb 09, 2022
vanguard group inc
9.21%
2,287,465
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 01, 2022
blackrock inc.
7.1%
1,768,081
SC 13G/A
Feb 10, 2021
vanguard group inc
9.18%
2,272,373
SC 13G/A
Feb 08, 2021
fmr llc
-
0
SC 13G
Jan 29, 2021
blackrock inc.
7.6%
1,892,336
SC 13G/A

BIO Fair Value

Bio Rad Laboratories fair value in different scenarios

The table shows the Fair Value estimates for Bio Rad Laboratories for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

234.47

-51.98%

269.94

-44.72%

384.70

-21.21%

469.38

-3.87%

567.20

16.16%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Bio Rad Laboratories Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Bio Rad Laboratories

View All Filings
Date Filed Form Type Document
Mar 08, 2023
4
Insider Trading
Feb 23, 2023
8-K
Current Report
Feb 17, 2023
10-K
Annual Report
Feb 16, 2023
8-K
Current Report
Feb 14, 2023
4
Insider Trading
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 01, 2023
SC 13G/A
Major Ownership Report
Jan 10, 2023
8-K
Current Report
Dec 19, 2022
4
Insider Trading
Norman D. Schwartz
7900
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

BIO Income Statement

2022-12-31
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended12 Months Ended
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]           
Net sales$ 730,300$ 680,800$ 691,100$ 700,100$ 732,800$ 747,000$ 715,900$ 726,800$ 2,802,249$ 2,922,545$ 2,545,626
Cost of Goods and Services Sold        1,234,9191,284,4491,107,739
Gross Profit397,100372,600395,000402,600399,900436,500401,100400,5001,567,3301,638,0961,437,887
Selling, general and administrative expense        827,825877,122798,798
Research and development expense        256,889260,638217,763
Income from operations        482,616500,336421,326
Interest expense        38,1141,55121,861
Foreign exchange losses, net        (205)2,7531,771
Debt and Equity Securities, Unrealized Gain (Loss)        5,193,554(4,926,248)(4,495,825)
Other (income) expense, net        (44,574)(26,775)(24,488)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest        (4,704,273)5,449,0554,918,007
Income Tax Expense (Benefit)        1,076,738(1,194,798)(1,103,778)
Net Income (Loss) Attributable to Parent$ 827,700$ (162,800)$ (925,100)$ (3,367,300)$ (1,572,200)$ 3,929,600$ 916,800$ 980,000$ (3,627,535)$ 4,254,257$ 3,814,229
Basic earnings per share:           
Earnings Per Share, Basic$ 27.89$ (5.48)$ (31.05)$ (112.5)$ (52.54)$ 131.80$ 30.80$ 32.86$ (121.79)$ 142.61$ 128.13
Weighted average common shares - basic        29,78529,83129,768
Diluted earnings per share:           
Earnings Per Share, Diluted$ 27.78$ (5.48)$ (31.05)$ (112.5)$ (52.54)$ 130.02$ 30.41$ 32.46$ (121.79)$ 140.83$ 126.47
Weighted average common shares - diluted        29,78530,20830,160

BIO Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
ASSETS:  
Cash and cash equivalents$ 434,215$ 470,783
Short-term investments1,356,457399,135
Restricted investments5,5605,560
Accounts receivable, less allowance for doubtful accounts494,645423,537
Inventories:  
Total inventories719,316572,239
Prepaid expenses124,179109,136
Other current assets23,60410,089
Total current assets3,157,9761,990,479
Property, plant and equipment:  
Land and improvements27,80527,940
Buildings and leasehold improvements393,620385,798
Equipment1,086,5951,099,741
Total property, plant and equipment1,508,0201,513,479
Less: accumulated depreciation and amortization(1,009,408)(1,001,840)
Property, plant and equipment, net498,612511,639
Operating Lease, Right-of-Use Asset180,952204,798
Goodwill406,488347,343
Intangible Assets, Net (Excluding Goodwill)332,147253,939
Other investments8,830,89214,387,006
Other assets94,599104,189
Total assets13,501,66617,799,393
LIABILITIES AND STOCKHOLDERS' EQUITY:  
Accounts payable135,041141,941
Accrued payroll and employee benefits194,790276,986
Current maturities of long-term debt465489
Income taxes payable11,92910,319
Accrual for Taxes Other than Income Taxes, Current20,49935,980
Current operating lease liabilities36,33636,435
Deferred revenue52,21150,852
Other current liabilities117,437127,936
Total current liabilities568,708680,938
Long-term debt, net of current maturities1,197,71610,514
Deferred Income Tax Liabilities, Net1,770,4813,064,576
Operating lease liabilities153,597175,938
Other long-term liabilities195,912182,191
Total liabilities3,886,4144,114,157
Commitments and contingent liabilities
Stockholders' equity:  
Preferred stock00
Additional paid-in capital447,454441,733
Retained earnings9,898,20313,525,343
Accumulated other comprehensive (loss) income(466,822)(175,553)
Stockholders' Equity Attributable to Parent9,615,25213,685,236
Total liabilities and stockholders' equity13,501,66617,799,393
Common Class A [Member]  
Stockholders' equity:  
Common stock22
Common Class B [Member]  
Stockholders' equity:  
Common stock11
Treasury Class-A [Member]  
Stockholders' equity:  
Treasury Stock, Value$ (263,586)$ (106,290)